Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × apaziquone × Clear all
NCT00141531 2012-06-14

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
53 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡